Changeflow GovPing Healthcare & Life Sciences FDA Guidance on EpCAM-Positive Cell Reduction b...
Routine Guidance Added Final

FDA Guidance on EpCAM-Positive Cell Reduction by Filters

Email

Summary

The FDA has issued guidance concerning the reduction of EpCAM-positive cells by filters. This document provides information relevant to drug manufacturers and medical device makers.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The FDA has released a guidance document related to the reduction of EpCAM-positive cells using filters. The document, identified by FDA-2025-N-5996-0030, is intended to provide clarity and information to regulated entities.

This guidance is primarily relevant to drug manufacturers and medical device makers involved in processes where EpCAM-positive cell reduction is a factor. Compliance officers should review the document to understand any implications for their product development, manufacturing, or quality control processes, although specific actionable steps or deadlines are not detailed in the provided information.

Archived snapshot

Mar 19, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

Content Restricted

Reason Restricted: Copyrighted

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Guidance
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Drug manufacturers Medical device makers Pharmaceutical companies
Geographic scope
National (US) National (US)

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Topics
Medical Devices Pharmaceuticals

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!